ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Resistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance that do not imply mutations in BCR/ABL have been also described. In the present rep...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Clara I Aceves-Luquero, Anupriya Agarwal, Juan L Callejas-Valera, Laura Arias-González, Azucena Esparís-Ogando, Luis del Peso Ovalle, Itxaso Bellón-Echeverria, Miguel A de la Cruz-Morcillo, Eva M Galán Moya, Inmaculada Moreno Gimeno, Juan C Gómez, Michael W Deininger, Atanasio Pandiella, Ricardo Sánchez Prieto
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2009
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/3dff57472bb442969456148bb3804193
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!